A genome-editing strategy to treat β-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition
Nature Medicine2016Vol. 22(9), pp. 987–990
Citations Over TimeTop 1% of 2016 papers
Elizabeth A. Traxler, Yu Yao, Yong‐Dong Wang, Kaitly J. Woodard, Ryo Kurita, Yukio Nakamura, Jim R. Hughes, Ross C. Hardison, Gerd A. Blobel, Chunliang Li, Mitchell J. Weiss
Related Papers
- → Unintended CRISPR-Cas9 editing outcomes: a review of the detection and prevalence of structural variants generated by gene-editing in human cells(2023)99 cited
- → CRISPR–Cas9 gene editing induced complex on-target outcomes in human cells(2022)34 cited
- → Challenges of in vitro genome editing with CRISPR/Cas9 and possible solutions: A review(2020)29 cited
- → CRISPR/Cas9 system: A promising technology for the treatment of inherited and neoplastic hematological diseases(2018)17 cited
- → Strategies for Optimization of the Clustered Regularly Interspaced Short Palindromic Repeat-Based Genome Editing System for Enhanced Editing Specificity(2021)2 cited